Tags · Evidence
effect size
Magnitude, not just direction or significance.
Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · PIONEER programme · SUSTAIN programme · LEADER trial · randomised trial · meta-analysis
214 topics · page 2 of 8
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Tracking semaglutide's approved indications across jurisdictions, dated
Tracking semaglutide's approved indications across jurisdictions, dated Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…
|
+15 | 19 | 2.8k | 1d |
|
Historical amylin analogues and what happened to them
Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. Proposing that historical amylin analogues deserves a maintained…
|
+29 | 36 | 31k | 1d |
|
Pooling trials with different estimands
On the subject in the title: Pooling trials with different estimands Working notes rather than a conclusion. Asking about pooling trials with different estimands on behalf of the question I keep seeing asked…
|
+120 | 132 | 2.3k | 1d |
|
A structured critique template this community uses
A structured critique template this community uses — setting out what I have, and where I think it stops being reliable. Structured critique template — I have the observation and I do not trust my…
|
2 | 18k | 1d | |
|
Selection into a registry and what it does to the estimate — a second dataset
Posting this under the heading it deserves: Selection into a registry and what it does to the estimate — a second dataset Everything below is what sits behind that. Posting a small dataset on Selection. It is…
|
+28 | 32 | 1.3k | 1d |
|
[2026 update] Journal club: what we got wrong in an earlier session
Journal club: what we got wrong in an earlier session — setting out what I have, and where I think it stops being reliable. Bringing a claim rather than a paper, because the claim is the thing circulating.…
|
+5 | 9 | 4.2k | 1d |
|
Publication bias detection and its low power
On the subject in the title: Publication bias detection and its low power Working notes rather than a conclusion. Working notes on publication bias detection rather than a conclusion. I would rather post the…
|
2 | 3.2k | 1d | |
|
What is genuinely unknown about long-term amylin agonism
What is genuinely unknown about long-term amylin agonism — that is the question, and I have not found it answered plainly anywhere I have looked. A comparison question rather than a question about one…
|
+83 | 91 | 46k | 1d |
|
Revisiting: How this community labels and discusses unrefereed work
Revisiting: How this community labels and discusses unrefereed work Writing it up because I had to work it out twice and would rather nobody else did. Reading an unrefereed manuscript properly, and asking…
|
+31 | 35 | 7k | 1d |
|
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. Reading SUSTAIN 6 ( N Engl J Med , 2016) for the population rather than the effect,…
|
+110 | 122 | 46k | 1d |
|
Follow-up: The retatrutide phase 2 obesity paper, read closely
The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. A follow-up question about retatrutide phase 2 obesity paper that I did not know to…
|
+19 | 23 | 16k | 2d |
|
Designing a personal experiment that could change your mind — one year on
Designing a personal experiment that could change your mind — one year on — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
+74 | 80 | 17k | 2d |
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction
The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. I would like to disagree…
|
+43 | 47 | 19k | 2d |
|
A pooled estimate that changed when one trial was added
A pooled estimate that changed when one trial was added — setting out what I have, and where I think it stops being reliable. I was wrong about pooled estimate in a thread last spring and I would like to…
|
+24 | 28 | 3.5k | 2d |
|
Coming back to: Why a preprint's supplementary material is often the best part
Why a preprint's supplementary material is often the best part — that is the question, and I have not found it answered plainly anywhere I have looked. A question about how this site should cite something…
|
+109 | 116 | 36k | 2d |
|
Blinding yourself: practical methods and their limits
On the subject in the title: Blinding yourself: practical methods and their limits Working notes rather than a conclusion. A methods question rather than a substantive one, about blinding yourself. Everyone…
|
+40 | 44 | 33k | 5d |
|
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…
|
+17 | 21 | 17k | 12d |
|
Second pass at: Cagrilintide molecular characteristics and analytical considerations
On the subject in the title: Second pass at: Cagrilintide molecular characteristics and analytical considerations Working notes rather than a conclusion. Something about Cagrilintide molecular characteristics…
|
4 | 5k | 21d | |
|
Sample size intuition for a personal experiment — does this still hold?
Sample size intuition for a personal experiment — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Reading back through what has been written…
|
+33 | 38 | 26k | 23d |
|
Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Setting out what I think I know about this compound and asking…
|
+5 | 9 | 13k | 25d |
|
Revisiting: Journal club: SURMOUNT-1, read without the press release
On the subject in the title: Revisiting: Journal club: SURMOUNT-1, read without the press release Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it…
|
+54 | 62 | 1.5k | 26d |
|
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Two things I would like separated before anyone answers…
|
+6 | 10 | 13k | 28d |
|
A plateau that disappeared when I changed how I measured — the long version
A plateau that disappeared when I changed how I measured — the long version — setting out what I have, and where I think it stops being reliable. A narrow question about plateau, deliberately narrow, because…
|
+49 | 54 | 9.4k | 1mo |
|
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I would like to know what…
|
+23 | 27 | 9.9k | 1mo |
|
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
|
2 | 52k | 1mo | |
|
Second pass at: A pooled estimate that changed when one trial was added
On the subject in the title: Second pass at: A pooled estimate that changed when one trial was added Working notes rather than a conclusion. Two things I would like separated before anyone answers on pooled…
|
+26 | 30 | 22k | 1mo |
|
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Posting a small dataset on SELECT. It is mine, it is…
|
4 | 1.3k | 1mo | |
|
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Something about Tirzepatide…
|
+109 | 122 | 3.6k | 2mo |
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. The question about…
|
+3 | 7 | 1k | 2mo |
|
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…
|
2 | 7.5k | 2mo |